Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis
Data from Dual-Acting Oral Biologic Show Promising Safety and Efficacy Profile
Posted in BioUtah News
Tagged Sorriso Pharmaceuticals
Comments Off on Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis
Sorriso Pharmaceuticals Announces First Patients Dosed in Phase 1b Clinical Trial for Patients with Ulcerative Colitis
Study to Evaluate SOR102, a Novel Oral Dual-Acting Antibody Targeting TNF⍺ and IL-23 (p19) for Inflammatory Bowel Disease
Posted in BioUtah News
Tagged Sorriso Pharmaceuticals
Comments Off on Sorriso Pharmaceuticals Announces First Patients Dosed in Phase 1b Clinical Trial for Patients with Ulcerative Colitis
Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions
Series A Financing Funds Multiple Programs to Phase 1 and IND stage
